Immunotherapy with subcutaneous low-dose interleukin-2 plus melatonin as salvage therapy of heavily chemotherapy-pretreated ovarian cancer

Oncology Reports

Volumn 3, Issue 5, 1996, Pages 947-949

  Lissoni, Paolo ^a   Ardizzoia, Antonio ^a   Barni, Sandro ^a   Tancini, Gabriele ^a   Muttini, Maria Pia ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b Ospedale di Carrara   (Italy)

Author keywords

immunotherapy; interleukin 2; melatonin; ovarian cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; MELATONIN; PACLITAXEL; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0029839011     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.3.5.947     Document Type: Article

References (14)

1. Copeland LJ, Gershenson DM and Wharton JT: Microscopic disease at second-look laparotomy in advance ovarian cancer. Cancer 55: 472-478, 1985.
2. Podratz KC, Malksian GD and Hilton JF: Second-look laparotomy in ovarian cancer: evaluation of pathological variables. Am J Obstet Gynecol 152; 230-233, 1985.
3. Smira LR, Stehman FB and Ulbright TM: Second-look laparotomy after chemotherapy in the management of ovarian malignancy. Am J Obstet Gynecol 152: 661-665, 1985.
4. Freedman RS: Recent immunologic advances affecting the management of ovarian cancer. Clin Obstet Gynecol 28: 853-871, 1985.
5. Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA: Lymphokine-activated killer cell phenomenon. J Exp Med 155: 1823-1841, 1982.
6. Talmadge JE: Therapeutic potential of cytokines: a comparison of pre-clinical and clinical studies. Prog Exp Tumor Res 32: 154-173, 1988.
7. Benedetti Panici P, Scambia G, Greggi S, Di Roberto P, Ragusa G, Perrone L, Sonsini C, Rumi C, Pourreau C, Palmer P, Franks CR and Mancuso S: Recombinant interleukin-2 continuous infusion in ovarian cancer patients with minimal residual disease at second-look. Cancer Treatment Rev 16: 123-127, 1989.
8. Lissoni P, Tisi E, Brivio F, Barni S, Rovelli F, Perego M and Tancini G: Increase in soluble interleukin-2 receptor and neopterin serum levels during imunotherapy of cancer with interleukin-2. Eur J Cancer 27: 1014-1016, 1991.
9. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Braillt H, Montero F, Joyeux I, Pouillart P and Fridman WH: Serum interleukin-6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 69: 911-913, 1994.
10. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y and Yoshida O: Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum by anti-interleukin-6 monoclonal antibody. Cancer Res 55: 590-596, 1995.
11. Malaguerra M, Scollo P, Ruggeri R, Caudullo S and Pistone G: Treatment of inoperable ovarian cancer with interleukin-2 and cisplatinum. Lancet 346: 1627, 1995.
12. Regelson W and Pierpaoli W: Melatonin: a rediscovered anti-tumor hormone? Cancer Invest 5: 379-385, 1987.
13. Lissoni P, Ardizzoia A, Barni S, Brivio F, Tisi E, Tancini G, Maestroni G and Fumagalli L: Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin: a progress report of 200 patients with advanced solid neoplasms. Oncol Rep 2: 1063-1068, 1995.
14. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL and Gastl GA: Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73: 1882-1888, 1994.